Swiss Economicblogs.org
Investec Switzerland. The soaring cost of some medicines has sparked a controversy that’s hampered drugmakers’ ability to raise prices in their biggest and most profitable market. © Robert Byron | Dreamstime.com Novartis AG Chief Executive Officer Joe Jimenez figures the golden days of unfettered price increases are over in the U.S. “Those days are over,” Jimenez said in a Bloomberg Television interview with Manus Cranny. “You have to assume that there is going to be...
Read More »Days of unfettered drug price increases over, Novartis head says.
